AFYX is based on the merger of three great and innovative companies bringing significant synergies together and thereby creating a commercial biopharmaceutical company with 3 late stage development programs and two products on the market. The companies were:
Lionheart, a company focused on the treatment of chronic and intermittent cluster headaches. A dramatic and severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication.
AFYX Therapeutics A/S, a company based on the development of proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.
Inphena A/S, a company that already has commercial activities in several countries and develops repurposed existing pharmaceutical substances for new indications.